Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multi-center, Open, One-arm Clinical Study Evaluating the Efficacy and Safety of Pegylated Recombinant Human Granulocyte-stimulating Factor Injection (PEG-rhG-CSF) in Preventing Neutropenia in Elderly Patients With Lymphoma After Chemotherapy

NCT03870412 is registered in ClinicalTrials.gov with CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. as lead sponsor.

NCT NCT03870412
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03870412 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multi-center, Open, One-arm Clinical Study Evaluating the Efficacy and Safety of Pegylated Recombinant Human Granulocyte-stimulating Factor Injection (PEG-rhG-CSF) in Preventing Neutropenia in Elderly Patients With Lymphoma After Chemotherapy
Lead sponsor
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Phase
Not applicable
Overall status
Unknown status
Start date
February 22, 2019
Completion date
August 22, 2021
Enrollment
485 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

elderly lymphoma patients